Sign inJoin waitlistJoin the waitlist

Surbhi Singhal

Assistant Professor, MED: Int Med Hematology/Oncology · University of California, Davis

Credentials: · · · ·

History

University of California, Davis
Present

National Institute on Aging
2022–2023
Hematology and Medical Oncology
Stanford Health Care
2017–2020
2019–2020
Internal Medicine
Stanford Health Care
2016–2017
University of Wisconsin School of Medicine and Public Health
2012–2016
University of Minnesota
2012

Research

Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review
Systematic review or meta-analysis · Journal of Pain and Symptom Management · 2019 · 49 citations
Cancer in a drop: Advances in liquid biopsy in 2024
Review · Critical Reviews in Oncology/Hematology · 2025 · 33 citations
Perceptions of time spent pursuing cancer care among patients, caregivers, and oncology professionals
Supportive Care in Cancer · 2021 · 25 citations

Heather Wakelee
7 papers
Jonathan Riess
6 papers
David Gandara
5 papers
Joel Neal
5 papers
Nathaniel Myall
5 papers
Kah Loh
4 papers
Kavitha Ramchandran
4 papers
Millie Das
4 papers
Mohamed Gouda
4 papers
Carolyn Presley
3 papers
Fangdi Sun
3 papers · 3 as a fellow
GW
Grant Williams
3 papers

Clinical trials

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Principal investigator · Recruiting · Phase 2
University of California, Davis
2026–2036
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2027
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2025–2029